- AASLD
American Association for the Study of Liver Disease
- Ab
antibody
- AE
adverse event
- ALT
alanine aminotransferase
- anti-HBc
antibody to hepatitis B core antigen
- APRI
AST-to-platelet ratio index
- ART
antiretroviral therapy
- ARV
antiretroviral
- AST
aspartate aminotransferase
- CI
confidence interval
- DAA
direct-acting antiviral (medicine)
- DBS
dried blood spot
- DDI
drug–drug interaction
- EASL
European Association for the Study of the Liver
- eGFR
estimated glomerular filtration rate
- EMA
European Medicines Agency
- FBC
full blood count
- FDA
United States Food and Drug Administration
- FDC
fixed-dose combination
- FIB-4
fibrosis-4 index for liver fibrosis
- GHP
Global Hepatitis Programme
- GHSS
Global Health Sector Strategy (on viral hepatitis)
- GRADE
Grading of Recommendations Assessment, Development and Evaluation
- HBsAg
hepatitis B surface antigen
- HBV
hepatitis B virus
- HCC
hepatocellular carcinoma
- HCV
hepatitis C virus
- HIC
high-income country
- HIV
human immunodeficiency virus
- LMICs
low- and middle-income countries
- MSF
Médecins Sans Frontières or Doctors Without Borders
- MSM
men who have sex with men
- NAT
nucleic acid testing/test
- NS5B
non-structural protein 5B (of HCV)
- NS3/NS4A
non-structural protein 3/non-structural protein 4A (of HCV)
- NSP
needle–syringe programme
- OR
odds ratio
- OST
opioid substitution therapy
- PEG-IFN
pegylated interferon
- PICO
Population, Intervention, Comparison, Outcomes
- PWID
people who inject drugs
- RBV
ribavirin
- RCT
randomized controlled trial
- RDT
rapid diagnostic test
- RNA
ribonucleic acid
- RR
relative risk
- SAE
severe adverse event
- STI
sexually transmitted infection
- SVR12
sustained virological response at 12 weeks post-treatment
- TB
tuberculosis
- UK
United Kingdom
- USA
United States of America
- WHO
World Health Organization
- WTO
World Trade Organization
Publication Details
Copyright
Sales, rights and licensing. To purchase WHO publications, see http://apps.who.int/bookorders. To submit requests for commercial use and queries on rights and licensing, see http://www.who.int/about/licensing.
Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.
Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO license (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo).
Under the terms of this license, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons license. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”.
Any mediation relating to disputes arising under the license shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization.
Publisher
World Health Organization, Geneva
NLM Citation
Guidelines for the Care and Treatment of Persons Diagnosed with Chronic Hepatitis C Virus Infection [Internet]. Geneva: World Health Organization; 2018 Jul. Abbreviations and Acronyms.